levoleucovorin calcium

P3, N=700, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P2, N=56, Active, not recruiting, Southwest Autism Research & Resource Center | Recruiting --> Active, not recruiting | N=134 --> 56 | Trial primary completion date: Jan 2025 --> Apr 2024

P1/2, N=107, Completed, NuCana plc | Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024

P2, N=66, Recruiting, Taiho Oncology, Inc. | N=26 --> 66

The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population.

P2, N=20, Completed, Asan Medical Center | Active, not recruiting --> Completed

P2, N=41, Not yet recruiting, Institut de Recherches Internationales Servier

P1, N=52, Recruiting, University Hospital, Grenoble | Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Nov 2025

P=N/A, N=757, Active, not recruiting, Takeda | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P2, N=20, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Nov 2023

Our study demonstrated prospectively that RAM plus FOLFIRI is an effective second-line treatment after anti-EGFR antibody-containing first-line therapy in RAS wild-type and left-sided mCRC. Furthermore, the results were similar for patients who were previously treated with triplet regimen.

P2, N=134, Recruiting, Southwest Autism Research & Resource Center | Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025

In 17 cases, the departments for the preparation of cytostatics in the Czech Republic had to accept restrictions on administering the full dose of leucovorin. These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches.

P2, N=26, Recruiting, Taiho Oncology, Inc. | Not yet recruiting --> Recruiting

The parallel administration of nal-IRI and Levo-LV is clinically safe and not inferior in efficacy. Moreover, parallel administration may offer convenience to patients and healthcare workers by reducing administration time.

P2, N=26, Not yet recruiting, Taiho Oncology, Inc.

P1/2, N=225, Recruiting, NuCana plc | Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Nov 2023

P1/2, N=91, Recruiting, NuCana plc | Not yet recruiting --> Recruiting

Levoleucovorin controlled cell proliferations in MDM-MB 231 and MCF-7 cells with GI50 values of 55.91 μM and 79.20 μM respectively. Further, a dose dependent inhibition of cancer cell migration was noted along with apoptosis induction in these cells with levoleucovorin treatment.Communicated by Ramaswamy H. Sarma.

Posterior reversible encephalopathy syndrome is a clinical and imaging syndrome characterized by endothelial dysfunction, blood-brain barrier disruption, and vasogenic edema. This is the first report that posterior reversible encephalopathy syndrome is caused by a thrombocytopenia regimen, and our case highlights the pathogenic role of a thrombocytopenia regimen in posterior reversible encephalopathy syndrome. However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study.

Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients.

P2, N=171, Recruiting, NuCana plc | Initiation date: Jan 2023 --> Apr 2023

P2, N=20, Not yet recruiting, Fujian Cancer Hospital

P3, N=890, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

FOLFOX as a subsequent treatment after failure of second-line treatment with 5FU/LV + nal-IRI is tolerable, although its efficacy is limited, particularly in patients with high CRP levels.

P1/2, N=225, Recruiting, NuCana plc | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023

P2, N=171, Recruiting, NuCana plc

P3, N=700, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

P3, N=890, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026

Ramucirumab [human vascular endothelial growth factor (VEGF) receptor-2 monoclonal antibody] + levofolinate, fluorouracil, and irinotecan (FOLFIRI) was approved for the treatment of metastatic colorectal cancer (CRC) in Japan based on the results from the phase 3 RAISE trial (NCT01183780)...Approximately 83.7% (n=303) and 25.4% (n=92) of patients had medication history of bevacizumab and anti-epidermal growth factor receptor (EGFR) antibodies, respectively...Although the current observational study enrolled patients with various medication history, the regimen of ramucirumab + FOLFIRI was manageable under clinical practice. No new safety concerns beyond the findings observed in previous clinical trials were reported.

Our biomarker study demonstrated no RAS mutations in ctDNA at disease progression in 62% of patients with RAS-mutant mCRC. Both OS and post-progression survival were better in patients with clearance of RAS mutations in ctDNA after triplet-based chemotherapy.

P3, N=400, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting

P3, N=400, Not yet recruiting, Seagen Inc.

P3, N=823, Completed, Takeda | Active, not recruiting --> Completed

P3, N=823, Active, not recruiting, Takeda | Trial completion date: Aug 2021 --> Jan 2022 | Trial primary completion date: Aug 2021 --> Jan 2022

P3, N=280, Recruiting, Azienda Unità Sanitaria Locale Reggio Emilia | Not yet recruiting --> Recruiting

P3, N=862, Recruiting, Merck Sharp & Dohme Corp. | Not yet recruiting --> Recruiting

P3, N=862, Not yet recruiting, Merck Sharp & Dohme Corp.

P3, N=280, Not yet recruiting, Azienda Unità Sanitaria Locale Reggio Emilia

5-Fluorouracil (5FU) seems to act differently depending on administration elastomer-mediated continuous infusion better inhibits Thymidylate Synthase (TS), an enzyme playing a pivotal role in DNA synthetic pathway. The simultaneous combination of 5FU and folinate salt synergistically strengthens fluorouracil cytotoxic effect. In our experience, levofolinate and 5FU together in continuous infusion prolong progression free survival of patients suffering from mCRC, moreover decreasing death risk and showing a clear clinical benefit for patients, irrespective of RAS mutational status, primitive tumor side and metastases surgery.

P3, N=790, Ongoing, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

P3, N=823, Active, not recruiting, Takeda | Trial completion date: Jun 2020 --> Aug 2021 | Trial primary completion date: Jun 2020 --> Aug 2021